If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...

Novo Nordisk’s stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly’s tirzepatide, marketed under the Zepbound and Mounjaro brands.The trial showed a weight loss of 20.2% with CagriSema versus 23.6% with tirzepatide, leading to a significant drop in Novo Nordisk shares.The REDEFINE 4 trial involved 809 subjects over 84 weeks, and while CagriSema demonstrated a safe profile, the results did not meet expectations.William Blair analyst An ...

SAN FRANCISCO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against Corcept Therapeutics Inc. (NASDAQ: CORT) and certain of its top executives. The lawsuit, Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525 (N.D. Cal.), seeks to recover losses for investors who purchased CORT common stock between October 31, 2024, and December 30, 2025 The fir ...

U.S. equity markets faced significant selling pressure during afternoon trading on Monday, February 23rd, 2026, as a combination of geopolitical trade uncertainty and renewed anxieties over the long-term impact of artificial intelligence (AI) weighed heavily on investor sentiment. The session was dominated by a sharp pivot toward risk-off behavior following a weekend of escalating trade rhetoric from the White House, effectively erasing the optimism seen late last week.Major Indexes Retreat in Afternoon Tra ...

从结构上看，钢铁、汽车以及部分医药产品此前谈判形成的特殊安排预计仍会保留，这些领域短期冲击相对有限。但除更多消费类商品和普通制造品将面临 与其他国家相同的关税环境。从威士忌到玩具等产品，过去依赖品牌和渠道优势的企业，如今不得不重新面对成本压力和市场份额的再分配。 英国政府一直把对美贸易关系当成一项重要成果对外宣传，此前双方沟通形成的框架中，英国商品进入美国市场大体适用约10%的对等关税水平，相比多数 国家处于更有利的位置，这让不少英国出口企业在价格竞争上占据一定空间。市场一度认为，在全球贸易摩擦加剧的背景下，这种相对优惠的安排将成为英 国稳定外贸的重要支撑。 然而美国方面提出将对各国普遍适用更高的关税水平，税率可能提升至15%。一旦这一方案全面执行，英国原本依赖的税率优势将明显削弱。相关机构测算 显示，在主要贸易伙伴中，英国面临的关税上调幅度可能最为明显，这意味着此前建立的竞争优势可能在短时间内被重新洗牌。 英国商界估算，若整体税率上行，对美出口成本可能增加约30亿英镑，涉及约4万家企业。对于依赖美国市场的制造商、消费品企业以及中小出口商来说， 利润空间将被明显压缩。一些企业已经开始重新评估订单结构和定价策略 ...

AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential On February 20, Barclays began coverage of AbbVie Inc. (NYSE:ABBV) with an Overweight rating. It set a price target of $275 on the stock. The firm said current consensus estimates do not fully reflect AbbVie’s operating leverage potential. In its note, Barclays added that positive results from any of the company’s proof-of-concept s ...

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract. ...

Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. Barclays Highlights Merck’s (MRK) Pipeline Catalysts in Coverage Initiation On February 20, Barclays started coverage of Merck & Co., Inc. (NYSE:MRK) with an Overweight rating. It set a $140 price target on the stock. The firm said the company’s 2026 will bring “first-in-class” launches and important data readouts that could shape its next phase of growth. The analyst added that Merck shares offer pote ...

Eli Lilly and Company (NYSE:LLY) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. Barclays Begins Coverage on Eli Lilly (LLY), Sees Strong Position in Obesity Market On February 20, Barclays initiated coverage of Eli Lilly and Company (NYSE:LLY) with an Overweight rating. The firm set a $1,350 price target on the stock. The firm said GLP-1 weight loss treatments represent a “durable structural shift,” reflecting growing confidence in the long-term demand for these therapies. The ...

Novo Nordisk Trips in the Obesity Race - Moby THE GIST Novo Nordisk just learned the hard way that in the obesity drug arms race, close is not good enough. A key head-to-head trial showed its next big shot failed to match Eli Lilly’s market leader, and investors responded by knocking about 15% off the stock in a single session. WHAT HAPPENED Novo Nordisk said its experimental once-weekly obesity injection CagriSema delivered 23% average weight loss after 84 weeks in a late stage trial. That compared with ...